Lilly leads the big pharma pack on pipeline value

Lilly leads the big pharma pack on pipeline value

Source: 
EP Vantage
snippet: 

Huge hopes for diabetes and Alzheimer’s projects swell Lilly’s pipeline valuation, with Glaxosmithkline and Abbvie looking bare in comparison.